Venous thromboembolism (VTE) represents both a significant health threat for at-risk patients and a financial burden. Meanwhile, provider organizations that fail to focus on and prevent VTE from ...

Venous thromboembolisms (VTE), or blood clots in the veins, affect as many as 900,000 Americans in the U.S. each year, about 50 percent of them are healthcare-associated, and as many as 70 percent of ...

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...

The geko device (FirstKind Ltd) is a battery powered, disposable neuromuscular electrostimulation device that is designed to increase venous blood flow, with the aim of reducing the risk of venous ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are ...

Please provide your email address to receive an email when new articles are posted on . Use of low-dose aspirin yielded a low risk of venous thromboembolism and medication-associated complications ...

MINNEAPOLIS — Risk for venous thromboembolism (VTE) appears substantially greater in patients with placenta accrete than in other pregnant patients, found a small single-center study presented at the ...

FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin PONTE VEDRA, Fla., April 9, 2024 /PRNewswire/ -- Cadrenal ...